

30th August 2022

- | | |
|---|--|
| <p>(1) BSE Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001</p> <p>Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051</p> <p>Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg</p> | |

Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,


In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations") and further to the intimation dated 15th July 2019, we hereby notify that Cipla (EU) Limited, ("Cipla EU"), wholly owned subsidiary of the Company in UK has agreed to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical Co. Ltd., a subsidiary of Cipla EU in China. Post-acquisition, Cipla EU's stake in the subsidiary, will increase to 93.10%.

Requisite details under SEBI Listing Regulations, 2015 read with Circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015 are enclosed as Annexure – I to this letter.

Please take the above information on record.

Thankyou

Yours faithfully,
For Cipla Limited



Rajendra Chopra
Company Secretary

Prepared by: Simona Dsouza

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380

Annexure – I

Details as per SEBI circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015

| Sr. No. | Particulars | Details |
|---------|---|---|
| a) | Name of the target entity, details in brief such as size, turnover etc.; | <p>Name of the target entity: Cipla (Jiangsu) Pharmaceutical Co. Ltd. (“JV Co.”)</p> <p>Brief Details: The JV Co. is a joint venture between Cipla (EU) Limited and Jiangsu XiDi Pharmaceuticals Co., Ltd (formerly known as Jiangsu Acebright Pharmaceuticals Co., Ltd), incorporated in 2019, in China, for the purpose of manufacturing, selling and distribution of pharmaceutical products, research and development services and analytical development services.</p> <p>Turnover: Nil as on 31st March 2022 since the JV Co. is yet to commence its operations</p> |
| b) | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”; | <p>The proposed acquisition is not a related party transaction under the Companies Act, 2013 or IND AS 24.</p> <p>For the limited purpose of Listing Regulations, the transaction is a related party transaction and will be at arm’s length.</p> <p>None of the promoter/promoter group/group companies have any interest in the entity.</p> |
| c) | Industry to which the entity being acquired belongs; | Pharmaceutical Industry |
| d) | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); | To provide quality drugs and strengthen presence in China. |
| e) | Brief details of any governmental or regulatory approvals required for the acquisition; | The acquisition of additional stake will be subject to (i) compliance with applicable laws and (ii) approvals from regulatory authorities in China. |
| f) | Indicative time-period for completion of the acquisition; | |

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380

| | | |
|----|---|---|
| g) | Nature of consideration - whether cash consideration or share swap and details of the same; | Conversion of existing shareholder's loan into capital. |
| h) | Cost of acquisition or the price at which the shares are acquired | USD 16.40 million. |
| i) | Percentage of shareholding / control acquired and / or number of shares acquired; | Upon completion of acquisition of additional stake, Cipla EU will hold 93.10% stake in the JV Co. |
| j) | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief) | <p>Brief background: Please refer (a) above</p> <p>Date of Incorporation: 8th August 2019</p> <p>History of last 3 years turnover: Nil since the JV Co. is yet to commence its operations.</p> <p>Country: China</p> |

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380